Abstract 233P
Background
Health is a state of complete wellbeing free from any discomfort and pain. Despite remarkable world-wide progress in the field of diagnostic, curative and preventive medicine, still there are large populations of people living in isolation in natural and unpolluted surroundings far away from civilisation, maintaining their traditional values, customs, beliefs and myths. India has the second largest tribal population of the world next to the African countries. The present study was conducted to assess the cancer awareness, tobacco use, and its effect on health among Malayali tribes, Yelagiri Hills, Tamil Nadu, India.
Methods
After a study among this population of 660 in 2010, extended research was carried out in 2018 among 2185 participants. The inhabitants of the 14 villages of the Yelagiri Hills, who were willing to participate in the study were included. Data was collected from a cross-sectional survey, using a survey proforma, clinical examination and a pre-tested questionnaire which included demographic data, tobacco habits. A brief tobacco cessation counseling was given to all the users. SPSS version 21 was used for statistical analysis.
Results
The study showed that among the 2185 study population, 47% had no formal education. Of those who had the habit of smoking, 29% smoked beedi, 31% smoked cigarettes, 39% chewed raw tobacco, 33% chewed Hans, and 12% had a combination of smoking and smokeless tobacco usage. Prevalence of oral mucosal lesions 47% and 7% oral cancer in the study population was due to tobacco usage and lack of awareness regarding the deleterious effects of the products used.
Conclusions
From the results of this study it may be concluded that the Malayali tribes were characterized by a lack of awareness about oral health, deep rooted dental beliefs, high prevalence of tobacco use and limited access to health services.
Clinical trial identification
Editorial acknowledgement
NA
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03